BEST-D Trial: Higher Doses of Vitamin D may be Required for Optimal Osteoporosis Prevention

Save

Osteoporosis is a major public health problems and is associated with a high burden of fractures and subsequent increased mortality.

Risk of GI Perforations on Biologics

Save

Gastrointestinal perforation is a rare but serious complication that RA patients may be at particular risk for.

Osteoporosis 2016 Year in Review - No new drug approvals, and a crisis in care

Save

No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise.

Female Physicians are Better in Death, Hospital Readmission Stats

Save

Do hospitalized Medicare beneficiaries treated by female internists have lower rates of 30-day mortality and hospital readmission than those patients treated by men? A new study published online by JAMA Internal Medicine suggests that they do.

EULAR 2016 Recommendations on Early Arthritis

Save

Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.

Lupus May Be at Increased Risk for Dementia

Save

Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) may occur in up to half of patients in their lifetime.

However, dementia is often not reported or studied in cohorts with neurologic disease in lupus. 

Rituximab May Reduce Mortality Risk in Rheumatoid Lung Disease

Save

While it is known that rheumatoid arthritis (RA) patients with interstitial lung involvement is associated with severe seropositive disease and is associated with an increased mortality.

CanVasc Recommendations for ANCA-Associated Vasculitis

Save

ANCA associated vasculitis (AAV) has undergone considerable study and advances in the last few years.

Nonsignificant CV Risk with Actemra vs Enbrel

Save

WASHINGTON -- Rheumatoid arthritis is a recognized risk factor for heart attacks and stroke, but a study comparing two leading biologics found only a non-significant increase in relative risk for patients treated with toclizimab (Actemra) vs etanercept (Enbrel), researchers reported here.

Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study

Save

The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.

Is ABT-494 the Next JAK Inhibitor?

Save

Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.

The RheumNow Week in Review – 2 December 2016

Save

Dr. Cush highlights reports from this week on RheumNow.com.

ASDAS Activity Correlates with Xray Progression in Spondyloarthritis

Save

Investigators analyzed a prospective study of patients with early axial spondyloarthritis (axSpA) to assess predictors of outcome.

Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial

Save

Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.

Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.

Save

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

RheumNow (ACR16) Week in Review – 18 November 2016

Save

Three Year Data on Secukinumab

Save

Dr. Philip Mease, MD presented the long-term efficacy and safety data for secukinumab in psoriatic arthritis (PsA) at the ACR Annual meeting in Washington, DC.

Celecoxib Shines and Naproxen Tanks in the PRECISION Study

Save

The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)

Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial

Save

Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.

Tocilizumab Infections Less in ACPA+ Patients

Save

Tocilizumab is in the spotlight at this year’s ACR 2016 meeting but there is still much to learn, including more about its safety profile. In an abstract presented at today’s poster session (Abstract 2618), Morel, et al.